RPN‐2 is highly expressed in breast cancer cells, in particular, in TNBC cancers, and correlates with metastasis and clinical tumor aggressiveness.30 The expression of the gene encoding RPN‐2 confers docetaxel resistance in breast cancer and RPN‐2 knockdown induces tumor cell apoptosis and sensitizes tumor cells to chemotherapy.31 Ribophorin‐II has also been shown to be responsible for the stabilization of mutant p53, the latter of which has 60–80% prevalence in TNBC cancers, and therefore constitutes a key driver of tumor development.32 The gene discussed is RPN2; the disease is cancer.